SUGAMMADEX KABI (Fresenius Kabi Australia Pty Ltd)
Product name
SUGAMMADEX KABI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
133 (255 working days)
Active ingredients
sugammadex sodium
Registration type
New generic medicine
Indication
Reversal of neuromuscular blockade induced by rocuronium or vecuronium in patients 2 years of age and older.